33322 Dupilumab improves patient-reported outcomes among adults with moderate-to-severe atopic dermatitis (AD) in clinical practice: 30-36 month results from the RELIEVE-AD study

Bruce Strober,Jingdong Chao,Chien-Chia Chuang,Min Yang,Brad Shumel,Jessie Wang,Gaelle Bego-Le-Bagousse,Debra Sierka,Zhixiao Wang,Dimittri Delevry

Journal of the American Academy of Dermatology（2022）

引用 1|浏览6

暂无评分

摘要

Introduction: This analysis of RELIEVE-AD, a prospective, longitudinal survey in US adults with moderate-to-severe AD, evaluates the long-term impact of dupilumab therapy on patient-reported AD flares, skin symptoms, itch, and sleep.

查看译文

关键词

dupilumab,patient-reported,moderate-to-severe

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要